Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
Pfizer Chief Calls Patent Pool ‘Nonsense’, Fears Tussle Over Vaccine
Pharma will oppose a patent pool, but the world still needs a way to guarantee fair access to COVID-19 vaccines.
Latecomer Merck Enters Coronavirus Vaccine Field With Themis Acquisition
While Moderna and others frontrunners aim for a 2020 emergency use approval, Merck believes a more deliberate approach will pay off in the long term.
Vaccine Manufacturing Hub Will Help UK Meet Coronavirus Challenge
Vaccine manufacturing capacity has been lost in the UK in recent decades. Now a new Vaccines Manufacturing Innovation Centre will re-seed that capacity and expertise - and the pandemic is accelerating its arrival.
Vaccine Manufacturing Hub Will Help UK Meet Coronavirus Challenge
Vaccines manufacturing capacity has been lost in the UK over recent decades. Now a new Vaccines Manufacturing Innovation Centre will re-seed that capacity and expertise - and the pandemic is accelerating its arrival.
Trump Is Taking Hydroxychloroquine – But Global Prevention Trial Is Deadly Serious
Experts fear Trump’s unregulated use of the malaria drug is dangerous, and muddies the waters around research which could still find chloroquine useful in preventing SARS-CoV-2 infection.
Moderna’s Early Data On COVID-19 Vaccine Prompts Dosing Revisions For Phase II
Move to lower doses could ease manufacturing scale-up burden a bit; first eight volunteers produced antibodies which match or surpass those seen in patients who have recovered from COVID-19 – but big test awaits in Phase III.